AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 311 min read$TRDA

MPM BioVentures 2014, L.P. (EVNIN LUKE, GADICKE ANSBERT) sold $616K of TRDA (indirect holdings)

MPM BioVentures 2014, L.P. sold 86,914 indirectly-held shares of Entrada Therapeutics, Inc. (TRDA) at an average of $7.08 ($6.99–$7.20, $0.62M total) across 3 trades over 2026-08-27 to 2026-08-31. Filed jointly with EVNIN LUKE (10% owner), GADICKE ANSBERT (10% owner), Foley Todd (10% owner), MPM BioVentures 2014 (B), L.P. (10% owner), MPM Asset Management Investors BV2014 LLC (10% owner), MPM BioVentures 2014 LLC (10% owner), MPM BioVentures 2014 GP LLC (10% owner), MPM BIOVENTURES 2018 (B), L.P. (10% owner) and MPM ASSET MANAGEMENT INVESTORS BV2018 LLC (10% owner).

Original reporting
SEC EDGAR · MPM BioVentures 2014, L.P., EVNIN LUKE, GADICKE ANSBERT, Foley Todd, MPM BioVentures 2014 (B), L.P., MPM Asset Management Investors BV2014 LLC, MPM BioVentures 2014 LLC, MPM BioVentures 2014 GP LLC, MPM BIOVENTURES 2018 (B), L.P., MPM ASSET MANAGEMENT INVESTORS BV2018 LLC
Published Aug 31, 2026, 10:25 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 31, 2026, 11:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TRDA
Bearish
medium confidence
Mentioned
$TRDA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TRDABearishLow
01

Why it matters

Provides primary source data on insider activity, useful for short-term sentiment assessment.

02

Market read

Insider sell of ~0.6M USD may cause modest price movement; relevant for short-term traders.

03

What to watch

Potential upcoming clinical data or financing events not disclosed.

Relevance 5/10Novelty 3/10Timing: Filed Aug 31 2026

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$TRDABearishMedium confidence
Context

Insider MPM BioVentures sold 86,914 shares of Entrada Therapeutics at $7.08 avg, total $615,777.

Expected impact

Potential slight downward pressure on TRDA price in the short term.

Evidence & confidence

The transaction size (~$0.6M) is small relative to market cap, but insider sell signals possible lack of confidence.

Market effects

Sector

Minimal impact on biotech sector; typical insider sell activity.

Regional

No significant regional effect.

Global

Limited to investors tracking Entrada Therapeutics.

Counterpoint

What could challenge this read

The sale could be a routine liquidity move, not a bearish signal.

Key entities

  • Company
    Entrada Therapeutics, Inc.

    Biotech firm listed on NASDAQ under ticker TRDA.

  • Investor
    MPM BioVentures 2014, L.P.

    Insider reporting a 10% ownership stake.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TRDA insider trading history →

Related articles

OCT 14
$TRDAMed

Entrada Therapeutics Advances Duchenne Study To Highest Planned Dose Level

Entrada Therapeutics (TRDA) will test its Duchenne muscular dystrophy therapy, ENTR-601-44, at the highest planned dose (18 mg/kg) in its Phase 1/2 study after a favorable safety review. The study aims to evaluate safety, tolerability, and effectiveness in patients aged 4 to 20. Data from earlier cohorts are expected by the end of 2026 and early 2027.

rttnews.com1 min
OCT 14
$TRDAMedAI 9/10

Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201…

Entrada Therapeutics, Inc. (TRDA) filed an SEC Form 8-K — Other Events. Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45 -- Cohort 1 met the primary objectives of favorable safety and tolerability at the initial dose of 5 m

SEC EDGAR 8-K2 min
OCT 14
$TRDAMedAI 8/10

Entrada reports phase 1/2 trial data for DMD therapy candidate

Entrada Therapeutics (TRDA) reported positive phase 1/2 trial data for ENTR-601-45 in Duchenne muscular dystrophy patients. The study met safety and tolerability goals, with treated patients showing increased dystrophin and exon skipping. Adverse events were mild. Cohort 2 data is expected in 2027. The company plans higher doses in subsequent cohorts.

investing.com2 min
OCT 14
$TRDAMedAI 8/10

Entrada receives clearance to test highest dose in DMD trial

Entrada Therapeutics (TRDA) advanced to the highest dose in its DMD trial after positive safety and pharmacokinetic data. The Phase 1/2 study, ELEVATE-44-201, is evaluating ENTR-601-44 for Duchenne muscular dystrophy. The company expects data from Cohort 1 by year-end 2026 and Cohort 2 in Q1 2027. ENTR-601-44 targets 8% of the global DMD patient population and received FDA Rare Pediatric Disease Designation in December 2025.

investing.com2 min